Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews;Wirksamkeit, Verträglichkeit und Sicherheit von Cannabinoiden für die Therapie von Chemotherapie-induzierter Übelkeit und Erbrechen: eine systematische Zusammenfassung systematischer Reviews

Schmerz

Volumn 30, Issue 1, 2016, Pages 14-24

  Tafelski, S ^a   Hauser W ^b,c   Schafer M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM SAARBRÜCKEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cannabinoids; Chemotherapy induced nausea and vomiting; Randomized controlled trial; Safety; Systematic review of systematic reviews; Tolerability

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; CANNABINOID; CHLORPROMAZINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOMPERIDONE; DOXORUBICIN; DRONABINOL; GABAPENTIN; HALOPERIDOL; LEVONANTRADOL; METHOTREXATE; METOCLOPRAMIDE; NABILONE; NABIXIMOLS; PLANT EXTRACT; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; THIETHYLPERAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT; MEDICAL CANNABIS;

ANTIEMETIC ACTIVITY; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); CHEMICALLY INDUCED; NAUSEA; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; MEDICAL MARIJUANA; NAUSEA; TREATMENT OUTCOME; VOMITING;

EID: 84958641153     PISSN: 0932433X     EISSN: 14322129     Source Type: Journal    
DOI: 10.1007/s00482-015-0092-3     Document Type: Article

References (30)

1. Ablin JN, Buskila D (2010) Emerging therapies for fibromyalgia: an update. Expert Opin Emerg Drugs 15:521–533
2. Aromataris E (2014) Joanna Briggs Institute Reviewers’ Manual: 2014 edition/Supplement. In:Joanna Briggs Institute
3. Basch E, Hesketh PJ, Kris MG et al (2011) Antiemetics: American society of clinical oncology clinical practice guideline update. J Oncol Pract 7:395–398
4. Craver C, Gayle J, Balu S et al (2011) Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 14:87–98
5. Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17:85–95
6. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066
7. Hesketh PJ (2004) Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Williston Park). 18:9–14
8. Higgins J, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration. Wiley-Blackwell, Hoboken
9. Hill KP (2015) Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313:2474–2483
10. Hoch E, Bonnetn U, Thomasius R et al (2015) Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int 112:271–278
11. Hocking CM, Kichenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 22:1143–1151
12. Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784
13. Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090
14. Keeley PW (2009) Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clin Evid 2009
15. Kreienberg R, Albert US, Follmann M et al (2013) Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: short version – AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL – Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd 73:556–583
16. Liu J, Tan L, Zhang H et al (2015) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care (Engl) 24:436–443
17. Machado Rocha FC, Stefano SC, De Cassia Haiek R et al (2008) Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 17:431–443
18. Palli SR, Grabner M, Quimbo RA et al (2015) The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag Res 7:175–188
19. Phillips RS, Gopaul S, Gibson F et al. (2010) Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev (9):CD007786
20. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–243
21. Santana TA, Trufelli DC, Matos LL et al (2015) Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer 23:213–222
22. Seo HJ, Kim KU (2012) Quality assessment of systematic reviews or meta-analyses of nursing interventions conducted by Korean reviewers. BMC Med Res Methodol 12:129
23. Shea BJ, Hamel C, Wells GA et al (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62:1013–1020
24. Smith LA, Azariah F, Lavender VT et al. (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 11:CD009464
25. Todaro B (2012) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 10:487–492
26. Tramer MR, Carroll D, Campbell FA et al (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:16–21
27. Van Den Elsen GA, Ahmed AI, Lammers M et al (2014) Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev 14:56–64
28. Van Sickle MD, Duncan M, Kingsley PJ et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332
29. Wang XF, Feng Y, Chen Y et al (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Scientific reports 4:4813
30. Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313:2456–2473